Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 815-825

  Qiu, Feng ^a   He, Xiao Jing ^a   Sun, Ya Xin ^a   Li Ling, Jesse ^a,b   Zhao, Li Mei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NORTHEASTERN UNIVERSITY   (China)

Author keywords

ABCB1; Bone marrow transplantation; Cyclosporine A; CYP3A4*18B; CYP3A5*3; Hematopoietic stem cell transplantation

Indexed keywords

CYCLOSPORIN A; GENOMIC DNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ABCB1 GENE; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GRAFT RECIPIENT; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 80051479206     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70594-1     Document Type: Article

References (49)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 1999, 39, 361-398. (Pubitemid 29222564)
2. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 2001, 11, 217-221. (Pubitemid 32319871)
3. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Ther Pharmacol, 2004, 75, 422-433. (Pubitemid 38534563)
4. Canadian Neoral Renal Transplantation Study Group: Absorption profiling of cyclosporin microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation, 2001, 72, 1024-1032.
5. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K: Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol, 2007, 64, 185-191. (Pubitemid 47063248)
6. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics, 2003, 13, 89-95. (Pubitemid 36259588)
7. Chu XM, Hao HP, Wang GJ, Guo LQ, Min PQ: Influence of CYP3A5 genetic polymorphism on cyclosporine Ametabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin, 2006, 27, 1504-1508.
8. Clase CM, Mahalati K, Kiberd BA, Lawen JG, West KA, Fraser AD, Belitsky P: Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplant, 2002, 2, 789-795. (Pubitemid 36342623)
9. Eng HS, Moharmed Z, Calne R, Lang CC, Mohd MA, Seet WT, Tan SY: The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int, 2006, 69, 1858-1864. (Pubitemid 43739216)
10. Evans WE, McLeod HL. Pharmacogenomics: Drug disposition, drug targets and side effects. N Engl J Med 2003, 348, 538-549. (Pubitemid 36159890)
11. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat, 2004, 23, 100.
12. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993, 62, 385-427. (Pubitemid 23237876)
13. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR et al.: Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos, 1999, 27, 161-166. (Pubitemid 29072066)
14. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 2004, 14, 147-154. (Pubitemid 38373108)
15. Hebert MF: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacroliums oral drug delivery. Adv Drug Deliv Rev, 1997, 27, 201-214.
16. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003, 74, 245-254. (Pubitemid 37083100)
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I et al.: Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000, 97, 3473-3478.
18. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D et al.: Effects of genetic of polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol, 2006, 33, 1093-1098. (Pubitemid 44581573)
19. Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH: Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica, 2007, 37, 315-327. (Pubitemid 46442598)
20. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 2001, 11, 773-779. (Pubitemid 33151512)
21. International Neoral Renal Transplantation Study Group: Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant, 2002, 2, 148-156.
22. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther, 2002, 72, 584-594. (Pubitemid 36237730)
23. Kahan B, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, Van Buren CT: Variable oral absorption of cyclosporine. Abiopharmaceutical risk factor for chronic renal allograft rejection. Transplantation, 1996, 62, 599-606. (Pubitemid 26313901)
24. Kelly P, Kahan BD: Review: metabolism of immunosuppressant drugs. Curr Drug Metab, 2002, 3, 275-287. (Pubitemid 34625040)
25. Kesten S, Scavuzzo M, Chaparro C, Szalai JP: Pharmacokinetic profile and variability of cyclosporine versus Neoral in patients with cystic fibrosis after lung transplantation. Pharmacotherapy, 1998, 18, 847-850. (Pubitemid 28341323)
26. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001, 70, 189-199. (Pubitemid 32777772)
27. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J: The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics, 2004, 14, 665-671. (Pubitemid 39411266)
28. Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporinemetabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther, 1988, 43, 630-635.
29. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001, 27, 383-391. (Pubitemid 32268418)
30. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, Mies S, Pollard SG et al.: Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation, 2002, 73, 953-959. (Pubitemid 34252362)
31. Lindholm A, Sawe J: Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Ther Drug Monit, 1995, 17, 570-573.
32. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB et al.: Role of intestinal P-glycoprotein (mdr1) in interpatient variationin the oral bioavailability of cyclosporine. Clin Pharmacol Ther, 1997, 62, 248-260. (Pubitemid 27417790)
33. Mander A: Haplotype frequency estimation using an EM algorithm and log-linear modelling. Stata Tech Bull Reprints, 2001, 10, 104-107.
34. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther, 2004, 75, 13-33. (Pubitemid 38130115)
35. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit, 2002, 24, 400-404. (Pubitemid 34553206)
36. Oellerich M, Armstrong VW, Schütz E, Shaw LM: Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem, 1998, 31, 309-316.
37. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD: Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics, 2000, 10, 373-388. (Pubitemid 30433571)
38. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK: Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol, 2008, 64, 1069-1084.
39. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK 506. J Biol Chem, 1993, 268, 6077-6080. (Pubitemid 23099291)
40. Sham PC: Statistics in human genetics. Arnold, London, 1998.
41. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA, 1987, 84, 7735-7738.
42. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T et al.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 2004, 78, 1182-1187. (Pubitemid 39426437)
43. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A: Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep, 2010, 62, 1159-1169.
44. Von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem, 2001, 47, 1048-1052. (Pubitemid 32493590)
45. Wacher VJ, Saiphati L, Benet LZ: Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev, 2001, 46, 89-102.
46. Wang W, Zhang XD, Guan DL, Lü YP, Ma LL, Hu XP, Zhang P et al.: Relationship between MDR1 polymorphism and blood concentration of cyclosporine A. Chin Med J (Engl), 2005, 118, 2097-2100. (Pubitemid 44848453)
47. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol, 2003, 43, 555-564. (Pubitemid 36613114)
48. Yin YQ, Li Y, Xu GL: Analysis of monitoring results on cyclosporine A plasma concentration in bone marrow transplantation recipients. China Pharmacy, 2009, 20, 833-836.
49. Zeng Y, He YJ, He FY, Fan L, Zhou HH: Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin, 2009, 30, 478-484.